MAR-Paliperidone Extended Release Tablets: Data Integrity
Last updated
Summary
Product
MAR-Paliperidone Extended Release tablets.
Issue
Health products - Product quality
What to do
See instructions below.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
MAR-Paliperidone |
MAR-Paliperidone 3mg |
DIN 02511010 |
Tablet (Extended-Release) |
Paliperidone 3 mg |
M210315 |
MAR-Paliperidone |
MAR-Paliperidone 6mg |
DIN 02511029 |
Tablet (Extended-Release) |
Paliperidone 6mg |
M210316 |
Issue
Data integrity concerns with product's bioequivalence data.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of Recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
|
Marcan Pharmaceuticals Inc. 2 Gurdwara Road, Suite #112, Ottawa, Ontario, K2E 1A2 |
Published by
Health Canada
Audience
General public
Health professionals
Hospitals
Recall class
Type II
Identification number
RA-63596
Get notified
Receive notifications for new and updated recalls and alerts by category.